Fig. 8

Targeting RARRES2 inhibits GBM progression and immune cell infiltration. A–B U251 and LN229 glioma cells were treated with siRARRES2 for 48 h. The EdU assay was used to detect glioma cell proliferation ability (bar: 100 µm). C–D U251 and LN229 glioma cells were treated with siRARRES2 for 48 h, and a colony formation assay was used to detect the colony formation ability of glioma cells. E U251 and LN229 glioma cells were treated with siRARRES2 for 48 h, and MTT assays were used to detect glioma cell viability. F The relative protein expression of RARRES2 in normal brain tissue and IDH (Mut) and IDH (WT) GBM tissues was assessed by Western blotting. Normal: normal brain tissue. IDH(Mut): IDH-mutant GBM tissue. IDH(WT): IDH wild-type GBM tissue. G–H The conditioned media was used to culture macrophages for 48 h, and the invasion ability of macrophages was analyzed by transwell assay (bar: 50 µm). Error bars: mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001